Discover Top Posts Tagged with #idenix

Novartis shows 45% jump in Q3 net profit

ZURICH: Swiss drugmaker Novartis reported better-than-expected results on Tuesday, as a pre-tax gain from the sale of its shareholding in Idenix offset full copycat competition to its former best-selling blood pressure pill Diovan.

The Basel-based firm reported a 45 percent jump in third-quarter net profit to $3.24 billion, ahead of the average forecast for $2.49 billion in a Reuters poll.